iuvantium

Executive Summary

Iuvantium is a UK-based precision immunology company founded in 2021, leveraging artificial intelligence and machine learning to discover and develop next-generation immune therapies. The company's name derives from the Latin 'iuvare' (to help) and 'adjuvant,' reflecting its focus on enhancing immune responses. Its vision is to enable the treatment and cure of diseases through precise modulation of the immune system. While detailed information on specific pipeline assets, funding, and stage is limited, iuvantium operates in the rapidly advancing field of immuno-oncology and autoimmune therapeutics, where AI-driven discovery is gaining traction. The company's private status and low profile suggest it may be in early preclinical or platform development stages, potentially seeking seed or Series A financing. Its location in London provides access to a strong biotech ecosystem and talent pool.

Upcoming Catalysts (preview)

• Q4 2024Announcement of Series A funding round60% success
• Q2 2025Presentation of preclinical data at major immunology conference50% success
• 2025Disclosure of lead candidate and therapeutic indication55% success